MHC tetramer detailed product information

Code No.	TS-M014-2
T-Select HLA-A*24:02 modified WT1 Tetramer-CYTWNQMNL-APC
Size	50 tests
Availability (in Japan)	1-9 （In Japan at 00:05, May 19, 2026 in JST）
Class	Class I
Animal species	Human
Category	cancer
Conjugate	APC
Immunogen (Antigen)	modified WT1
Sequence	CYTWNQMNL
MHC Allele	A*24:02
Location (aa)	235-243
Storage temp.	4°C
Manufacturer	MBL
Product category	Research area:Immunology Tools:MHC tetramer
Citations	Narita M, et al., WT1 peptide vaccination in combination with imatinib therapy for a patient with CML in the chronic phase. Int J Med Sci. 7: 72?\|81 (2010)(PMID:20428337) Saitoh A, et al., WT1 peptide vaccination in a CML patient: induction of effective cytotoxic T lymphocytes and significance of peptide administration interval. Med. Oncol. 28: 219?\|230 (2011)(PMID:20107936) Chiba Y, et al., Effects of concomitant temozolomide and radiation therapies on WT1-specific T-cells in malignant glioma. Jpn. J. Clin. Oncol. 40: 395?\|403 (2010)(PMID:20364021) Tsuboi A, et al., Wilms tumor gene WT1 peptide-based immunotherapy induced a minimal response in a patient with advanced therapy-resistant multiple myeloma. Int. J. Hematol. 86: 414?\|417 (2007)(PMID:18192109) Lu X et al. Co-inhibition of TIGIT, PD1, and Tim3 reverses dysfunction of Wilms tumor protein-1 (WT1)-specific CD8+ T lymphocytes after dendritic cell vaccination in gastric cancer. Am J Cancer Res. 8, 1564-1575 (2018)(PMID:30210924)

The availability is based on the information in Japan at 00:05, May 19, 2026 in JST.
The special price is shown in red color.
Please note that products cannot be ordered from this website. To purchase the items listed in this website, please contact us or local distributers.
For storage temparature: RT: room temparature
Please note that products in this website might be changed or discontinued without notification in advance for quality improvement.